Drugs / Virus Activated Killer immune Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05565014 | Jul 2020 → Dec 2023 | peritoneal neoplasm, pleural neoplasm | Sheng Hu | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Virus Activated Killer immune Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565014 ↗ |
| Known as | VAK | “Virus Activated Killer immune Cells（VAK）” NCT05565014 ↗ |
| Action | Deplete | “to kill tumor cells in malignant pleural and peritoneal fluid” NCT05565014 ↗ |
| Route | Other | “30-50ML of prepared lymphocytes (qualified by PCR sterility test and endotoxin test) were infused into the chest and abdominal cavity of the patient.” NCT05565014 ↗ |